Svb Leerink initiated coverage on shares of Tocagen (NASDAQ:TOCA) in a research report released on Monday morning, BenzingaRatingsTable reports. The firm issued a market perform rating and a $11.00 price objective on the stock.
TOCA has been the topic of a number of other research reports. B. Riley started coverage on shares of Tocagen in a report on Monday, December 31st. They set a buy rating and a $22.00 price target on the stock. Zacks Investment Research upgraded shares of Tocagen from a hold rating to a buy rating and set a $10.00 price target on the stock in a report on Tuesday, January 15th. Robert W. Baird started coverage on shares of Tocagen in a report on Friday, January 18th. They set an outperform rating and a $20.00 price target on the stock. Finally, Leerink Swann started coverage on shares of Tocagen in a report on Monday. They set a market perform rating and a $10.26 price target on the stock. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $18.58.
Shares of TOCA opened at $9.94 on Monday. The stock has a market capitalization of $236.19 million, a price-to-earnings ratio of -4.07 and a beta of 3.50. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.91 and a current ratio of 5.91. Tocagen has a fifty-two week low of $6.47 and a fifty-two week high of $15.80.
Tocagen (NASDAQ:TOCA) last announced its quarterly earnings data on Wednesday, February 27th. The company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.35). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Tocagen had a negative return on equity of 92.56% and a negative net margin of 271.43%. As a group, equities analysts predict that Tocagen will post -2.94 earnings per share for the current year.
Large investors have recently bought and sold shares of the company. Meeder Asset Management Inc. grew its holdings in shares of Tocagen by 162.8% during the fourth quarter. Meeder Asset Management Inc. now owns 9,961 shares of the company’s stock valued at $82,000 after buying an additional 6,170 shares during the last quarter. Stratos Wealth Partners LTD. grew its holdings in shares of Tocagen by 9.0% during the fourth quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock valued at $94,000 after buying an additional 949 shares during the last quarter. Caption Management LLC purchased a new stake in shares of Tocagen during the fourth quarter valued at approximately $98,000. Bank of America Corp DE grew its holdings in shares of Tocagen by 28.6% during the fourth quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after buying an additional 3,240 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Tocagen in the third quarter worth approximately $251,000. Hedge funds and other institutional investors own 36.88% of the company’s stock.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Read More: What is the strike price in options trading?
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.